Introduction
Macrolide antibiotics are used to treat respiratory tract infections such as community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis, pharyngitis, acute bacterial sinusitis and otitis media, including infections caused by Chlamydia pneumoniae, Mycoplasma pneumoniae and Legionella. ABT-773 is an erythromycin derivative in which a ketone group replaces the cladinose at the 3-position of the macrolactone ring, and which contains an O-allyl-3-quinoline at the 6-position and a cyclic carbamate group between the 11-and 12-positions. It demonstrates potent in vitro antibacterial activity and in vivo efficacy against respiratory tract pathogens, including erythromycin-resistant streptococci having either dimethylation of the 23S rRNA by Erm methylases or macrolide-specific efflux pumps. 1 The MIC 90 of ABT-773 for 1601 antibiotic-susceptible and -resistant isolates of Streptococcus pneumoniae is 0.03 mg/L. 2 The MIC 90 s of ABT-773 are 4 and 0.06 mg/L for Haemophilus influenzae and Moraxella catarrhalis, respectively. 2 In this study, the frequency at which ABT-773, erythromycin and rifampicin selected for mutants with reduced susceptibility in vitro was assessed using 12 respiratory tract pathogens. Susceptibilities of the mutants to ABT-773, erythromycin, clindamycin and ciprofloxacin were then evaluated. 
Materials and methods

Antibiotics and media
Selection of mutants
MICs for the parent strains were determined by agar dilution as described by the NCCLS 4 in MHA for Staphylococcus aureus, MHA containing 5% sheep blood for streptococci or Haemophilus Test agar for H. influenzae. Plates were inoculated with 10 4 cfu per spot, and incubated at 36°C in ambient air for 16-20 h for S. aureus or in an atmosphere containing 5% CO 2 for 20-24 h for streptococci and H. influenzae.
Parent strains of S. aureus were grown overnight in MHB at 36°C in ambient air. The cultures were concentrated by centrifugation at 600g for 15 min and the cell pellet was resuspended in broth at 1/10 the original volume. Parent strains were grown overnight at 36°C in an atmosphere containing 5% CO 2 on three plates of MHA containing 5% sheep blood for the streptococci or Haemophilus Test agar for H. influenzae. Colonies were harvested and resuspended in MHB containing 3% lysed horse blood for the streptococci or MHB containing 15 µg/L haematin, 5 g/L yeast extract and 15 mg/L NAD for H. influenzae. The number of cfu per mL in the inocula was determined on drug-free agar media following overnight incubation. Concurrently, 10 plates of agar media containing ABT-773, erythromycin or rifampicin were inoculated with 0.1 mL of the concentrated suspension of staphylococci or H. influenzae, whereas 20 plates were used for selections from S. pneumoniae by ABT-773. Selection plates were incubated at 36°C for up to 72 h in ambient air for S. aureus or in an atmosphere containing 5% CO 2 for streptococci and H. influenzae, and the numbers of cfu per mL were determined. The selection frequency was calculated as the number of cfu per mL on antibiotic-containing medium divided by the number of cfu per mL in the original inoculum. Up to 10 colonies per selecting condition for experiments with ABT-773 and erythromycin or two colonies per selecting condition for experiments with rifampicin were subcultured on to the same drug selection agar and were then maintained on drug-free medium.
Determination of antibacterial activity
Susceptibilities for parent strains and mutants were determined by the broth microdilution method. 4 Quality control met NCCLS standards. 4
Results and discussion
Frequency of selection of mutants
Mutants with reduced susceptibility to ABT-773 and erythromycin were selected on agar media containing drug concentrations 4-16 × MIC from 12 strains of respiratory tract pathogens using inocula ranging from 10 9 to 10 12 cfu. Additionally, selection was carried out with ABT-773 and rifampicin at 2 × MIC (Table 1) . Six strains were erythromycin susceptible and six were erythromycin resistant [inducible Erm(A) in S. aureus and Streptococcus pyogenes, Erm(B) in S. pneumoniae and S. pyogenes, and Mef(A) in S. pneumoniae and S. pyogenes]. All strains were rifampicin susceptible.
S. aureus mutants were isolated on up to 16 × MIC by ABT-773 and erythromycin within 48 h. Mutants were selected more frequently by erythromycin than ABT-773. In addition, the selection of mutants from the inducible Erm(A) strain was 10-fold and 10 5 -fold more frequent than from susceptible strains for ABT-773 and erythromycin, respectively.
S. pneumoniae mutants were selected at 72 h by ABT-773 from the erythromycin-susceptible, Mef(A) and Erm(B) strains at frequencies of 10 -10 to 10 -12 at 2-4 × MIC, and by erythromycin from the Mef(A) strain at a frequency of 10 -8 at 4-16 × MIC.
S. pyogenes mutants were selected at 72 h by ABT-773 at a frequency of 10 -10 from the Mef(A) strain at 2 × MIC and from the Erm(B) strain at 2 × and 4 × MIC. Mutants were selected from the inducible Erm(A) strain at high frequency by erythromycin at 4-16 × MIC.
H. influenzae mutants were not selected by ABT-773 or erythromycin.
Mutants were selected more frequently by rifampicin than by ABT-773 or erythromycin for 12/12 or 8/12 strains, respectively. Moreover, rifampicin mutants were selected as frequently on 16 × as on 2 × MIC for 11/12 strains.
Phenotypes of mutants derived by selection
Most of the ABT-773 and erythromycin mutants demonstrated increased MICs of both compounds, and some also demonstrated changes in clindamycin MICs (Table 2 ). More than one profile, defined as diverging effects on ABT-773, erythromycin and clindamycin susceptibility, was found in mutants derived from seven strains. In contrast, parent strains and mutants had identical ciprofloxacin MICs (data not shown). Rifampicin MICs increased from ≤0.12 to >32 mg/L with unchanged ABT-773 and ciprofloxacin MICs in mutants selected by rifampicin, consistent with mutations in DNA-dependent RNA polymerase (data not shown). 5 The most frequent phenotype selected from erythromycinsusceptible S. aureus was selected by ABT-773 and erythromycin, and had ABT-773 MICs that were increased c. 32-fold and erythromycin MICs that were increased c. 64-fold. ABT-773 selected a second phenotype with higher ABT-773 MICs, and erythromycin selected a third phenotype with higher erythromycin MICs. Two divergent phenotypes were selected from the inducible Erm(A) S. aureus strain: highlevel cross-resistance to ABT-773, erythromycin and clindamycin, selected by ABT-773, and high-level resistance to erythromycin selected by erythromycin. Strain genotypes found in Table 1 . Two mutants with ABT-773 MICs of 0.25 or 2 mg/L were selected from the erythromycin-susceptible strain of S. pneumoniae by ABT-773; they had increased erythromycin MICs and decreased clindamycin MICs. Four phenotypes selected from Mef(A) S. pneumoniae by ABT-773 or erythromycin were distinguished by susceptibility to ABT-773 and clindamycin, although erythromycin MICs were similar. ABT-773 MICs were elevated to either 0.03 or 0.5 mg/L for two mutants selected from Erm(B) S. pneumoniae by ABT-773.
Resistance was not stable after drug-free passage of mutants selected from the inducible Erm(A) S. pyogenes by erythromycin. Two phenotypes were selected from Mef(A) S. pyogenes by ABT-773 in which the ABT-773 and erythromycin MICs increased to similar levels although clindamycin MICs were different. One phenotype was selected from the Erm(B) strain of S. pyogenes by ABT-773, which increased the ABT-773 MIC two-to four-fold.
Erythromycin, telithromycin and clindamycin share overlapping binding sites near the peptidyl transferase centre of the ribosome. 6, 7 Mutations at A2058, A2059 and C2611 in domain V of 23S rRNA and in ribosomal protein L4 selected from S. pneumoniae with azithromycin in vitro, 8 at U754 in domain II of 23S rRNA selected from a library of Escherichia coli strains by telithromycin in vitro, 7 and at A2059 of the 23S rRNA and in ribosomal protein L4 in clinical isolates of S. pneumoniae 9 result in cross-resistance to macrolides, clindamycin and telithromycin. The patterns of reduced susceptibility to ABT-773, erythromycin and clindamycin indicate that the mutations selected in vitro by ABT-773 and erythromycin may reside in genes associated with the macrolide-binding site. Moreover, ABT-773, erythromycin and clindamycin may interact differently with the ribosome since mutant profiles were identified that showed divergent effects on the relative loss of susceptibility to each compound. In addition, mutants derived from the Erm strains may have altered ribosome methylation since ketolide susceptibility in Erm(B) S. pneumoniae is proportional to the level of ribosome methylation, 10 and non-inducing macrolides select for constitutive expression of inducible erm genes, resulting in high-level cross-resistance to macrolides and clindamycin. 6 In conclusion, ABT-773 at concentrations above the MIC did not select for mutants with reduced susceptibility from four strains of respiratory tract pathogens, and selected mutants very infrequently from eight other strains. Moreover, the frequency of selection of mutants from erythromycin-resistant and -susceptible streptococci was similar. Except for mutants selected from inducible Erm(A) S. aureus, ABT-773 MICs for mutants ranged from 0.015 to
